Matches in SemOpenAlex for { <https://semopenalex.org/work/W3091441011> ?p ?o ?g. }
- W3091441011 endingPage "839" @default.
- W3091441011 startingPage "828" @default.
- W3091441011 abstract "Evidence for the effectiveness of vitiligo treatments is limited. To determine the effectiveness of (i) handheld narrowband UVB (NB‐UVB) and (ii) a combination of potent topical corticosteroid (TCS) and NB‐UVB, compared with TCS alone, for localized vitiligo. A pragmatic, three‐arm, placebo‐controlled randomized controlled trial (9‐month treatment, 12‐month follow‐up). Adults and children, recruited from secondary care and the community, aged ≥ 5 years and with active vitiligo affecting < 10% of skin, were randomized 1 : 1 : 1 to receive TCS (mometasone furoate 0·1% ointment + dummy NB‐UVB), NB‐UVB (NB‐UVB + placebo TCS) or a combination (TCS + NB‐UVB). TCS was applied once daily on alternating weeks; NB‐UVB was administered on alternate days in escalating doses, adjusted for erythema. The primary outcome was treatment success at 9 months at a target patch assessed using the participant‐reported Vitiligo Noticeability Scale, with multiple imputation for missing data. The trial was registered with number ISRCTN17160087 on 8 January 2015. In total 517 participants were randomized to TCS (n = 173), NB‐UVB (n = 169) and combination (n = 175). Primary outcome data were available for 370 (72%) participants. The proportions with target patch treatment success were 17% (TCS), 22% (NB‐UVB) and 27% (combination). Combination treatment was superior to TCS: adjusted between‐group difference 10·9% (95% confidence interval 1·0%–20·9%; P = 0·032; number needed to treat = 10). NB‐UVB alone was not superior to TCS: adjusted between‐group difference 5·2% (95% CI − 4·4% to 14·9%; P = 0·29; number needed to treat = 19). Participants using interventions with ≥ 75% expected adherence were more likely to achieve treatment success, but the effects were lost once treatment stopped. Localized grade 3 or 4 erythema was reported in 62 (12%) participants (including three with dummy light). Skin thinning was reported in 13 (2·5%) participants (including one with placebo ointment). Combination treatment with home‐based handheld NB‐UVB plus TCS is likely to be superior to TCS alone for treatment of localized vitiligo. Combination treatment was relatively safe and well tolerated but was successful in only around one‐quarter of participants." @default.
- W3091441011 created "2020-10-08" @default.
- W3091441011 creator A5000556586 @default.
- W3091441011 creator A5003316836 @default.
- W3091441011 creator A5007440428 @default.
- W3091441011 creator A5013785861 @default.
- W3091441011 creator A5016401447 @default.
- W3091441011 creator A5020273160 @default.
- W3091441011 creator A5020714761 @default.
- W3091441011 creator A5021361003 @default.
- W3091441011 creator A5023140996 @default.
- W3091441011 creator A5027596281 @default.
- W3091441011 creator A5028646703 @default.
- W3091441011 creator A5032729175 @default.
- W3091441011 creator A5033431709 @default.
- W3091441011 creator A5035195162 @default.
- W3091441011 creator A5035562567 @default.
- W3091441011 creator A5039368398 @default.
- W3091441011 creator A5041091450 @default.
- W3091441011 creator A5041320254 @default.
- W3091441011 creator A5046999262 @default.
- W3091441011 creator A5055091713 @default.
- W3091441011 creator A5055634988 @default.
- W3091441011 creator A5057300951 @default.
- W3091441011 creator A5057856246 @default.
- W3091441011 creator A5060149271 @default.
- W3091441011 creator A5066910927 @default.
- W3091441011 creator A5067179548 @default.
- W3091441011 creator A5070207982 @default.
- W3091441011 creator A5072258821 @default.
- W3091441011 creator A5077659318 @default.
- W3091441011 creator A5077796951 @default.
- W3091441011 creator A5080789912 @default.
- W3091441011 creator A5085209795 @default.
- W3091441011 creator A5091195952 @default.
- W3091441011 date "2020-12-28" @default.
- W3091441011 modified "2023-10-01" @default.
- W3091441011 title "Randomized controlled trial of topical corticosteroid and home‐based narrowband ultraviolet B for active and limited vitiligo: results of the HI‐Light Vitiligo Trial*" @default.
- W3091441011 cites W1496673882 @default.
- W3091441011 cites W1498880273 @default.
- W3091441011 cites W1557652270 @default.
- W3091441011 cites W1901084977 @default.
- W3091441011 cites W1904850091 @default.
- W3091441011 cites W1948267598 @default.
- W3091441011 cites W1985595328 @default.
- W3091441011 cites W1996295606 @default.
- W3091441011 cites W1999832688 @default.
- W3091441011 cites W2003231569 @default.
- W3091441011 cites W2005682090 @default.
- W3091441011 cites W2008413924 @default.
- W3091441011 cites W2013565436 @default.
- W3091441011 cites W2044794199 @default.
- W3091441011 cites W2059119358 @default.
- W3091441011 cites W2068191114 @default.
- W3091441011 cites W2070567299 @default.
- W3091441011 cites W2098687312 @default.
- W3091441011 cites W2099668282 @default.
- W3091441011 cites W2118502261 @default.
- W3091441011 cites W2119255075 @default.
- W3091441011 cites W2122398651 @default.
- W3091441011 cites W2123368313 @default.
- W3091441011 cites W2124149851 @default.
- W3091441011 cites W2129310091 @default.
- W3091441011 cites W2131794452 @default.
- W3091441011 cites W2161815451 @default.
- W3091441011 cites W2162101368 @default.
- W3091441011 cites W2168745210 @default.
- W3091441011 cites W2527192536 @default.
- W3091441011 cites W2555544739 @default.
- W3091441011 cites W2588163652 @default.
- W3091441011 cites W2602909938 @default.
- W3091441011 cites W2603241315 @default.
- W3091441011 cites W2603904648 @default.
- W3091441011 cites W2780049904 @default.
- W3091441011 cites W2782738549 @default.
- W3091441011 cites W2883295760 @default.
- W3091441011 cites W3085742189 @default.
- W3091441011 cites W4210353848 @default.
- W3091441011 cites W4255696556 @default.
- W3091441011 doi "https://doi.org/10.1111/bjd.19592" @default.
- W3091441011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33006767" @default.
- W3091441011 hasPublicationYear "2020" @default.
- W3091441011 type Work @default.
- W3091441011 sameAs 3091441011 @default.
- W3091441011 citedByCount "22" @default.
- W3091441011 countsByYear W30914410112020 @default.
- W3091441011 countsByYear W30914410112021 @default.
- W3091441011 countsByYear W30914410112022 @default.
- W3091441011 countsByYear W30914410112023 @default.
- W3091441011 crossrefType "journal-article" @default.
- W3091441011 hasAuthorship W3091441011A5000556586 @default.
- W3091441011 hasAuthorship W3091441011A5003316836 @default.
- W3091441011 hasAuthorship W3091441011A5007440428 @default.
- W3091441011 hasAuthorship W3091441011A5013785861 @default.
- W3091441011 hasAuthorship W3091441011A5016401447 @default.
- W3091441011 hasAuthorship W3091441011A5020273160 @default.
- W3091441011 hasAuthorship W3091441011A5020714761 @default.
- W3091441011 hasAuthorship W3091441011A5021361003 @default.